Inflammation, Intracellular Invasion and Colonization of the Nasal Mucosa by Staphylococcus Aureus (I3COSa)

C

Centre Hospitalier Universitaire de Saint Etienne

Status

Enrolling

Conditions

Healthy

Treatments

Diagnostic Test: nasal swab

Study type

Interventional

Funder types

Other

Identifiers

NCT04469348
19CH050
2020-A00321-38 (Other Identifier)

Details and patient eligibility

About

An inflammatory state of the nasal cells (very close to keratinocytes) could favour the internalization of Staphylococcus aureus and thus constitute a persistent reservoir for the carriage of this bacterium. Staphylococcus aureus is a commensal bacterium of the skin and mucous membranes that colonizes approximately 2 billion people worldwide Staphylococcus aureus is also a leading cause of community and healthcare-associated infection. Staphylococcus aureus has demonstrated its ability to invade many non-professional phagocytic cell lines such as keratinocytes, osteoblasts, fibroblasts, epithelial cells and endothelial cells. During pro-inflammatory stimulation, internalization of Staphylococcus aureus into keratinocytes is mainly mediated by ICAM-1. These results suggest that, in humans, an inflammatory state of the nasal cells (very close to keratinocytes) could promote the internalization of Staphylococcus aureus and thus constitute a persistent reservoir for the carriage of this bacterium.

Full description

The main objective is to compare the expression level of ICAM-1 in nasal cells with and without the presence of Staphylococcus aureus.

Enrollment

157 estimated patients

Sex

All

Ages

18+ years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Subject affiliated to a social security scheme or entitled person
  • Subject who received informed information about the study et signed consent
  • Adult subject (≥18ans)
  • Healthy Volunteer

Exclusion criteria

  • Subject undergoing antibiotic treatment or having received antibiotic treatment (oral, IV or local) in the month prior to inclusion
  • Subject with a major haemostasis disorder or anticoagulant treatment contraindicated for surgery
  • Subject with a pathology increasing the nasal carriage of S. aureus (chronic furunculosis, diabetes, HIV infection, chronic rhinosinusitis)
  • Subject under guardianship or trusteeship
  • Pregnant woman

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

157 participants in 1 patient group

Healthy volunteers
Experimental group
Description:
Healthy volunteers will be included. They will have nasal swab at the inclusion visit to detect contamination of S. Aureus. If contamination of S. Aureus: they will have 12 follow-up visits (1 per month) If no contamination of S. Aureus: their participation stops
Treatment:
Diagnostic Test: nasal swab

Trial contacts and locations

1

Loading...

Central trial contact

Florence RANCON, CRA; Paul Verhoeven, MD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems